Results 101 to 110 of about 1,081,250 (402)
AAV2.7m8 serotype combined with the gfaABC1D promoter targets infection of supporting cells (SCs). AAV2.7m8‐gfaABC1D‐Gjb2 administration to mice results in excessive immune responses. The combination of AAV2.7m8‐gfaABC1D‐Gjb2 with dexamethasone (DEX) shows a synergistic effect and enhances the gene therapy effect in a conditional Cx26 null mice model ...
Xiaohui Wang+8 more
wiley +1 more source
Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C [PDF]
Hepatitis C virus (HCV) is the main cause of chronic liver disease and cirrhosis in Western countries. Over time, the majority of cirrhotic patients develop hepatocellular carcinoma (HCC), one of the most common fatal cancers worldwide - fourth for ...
Fassina, Giorgio+3 more
core +1 more source
This study constructs a stacked multimodal machine learning model for nonalcoholic fattly liver disease (NAFLD) by integrating genetic and clinical features, and synthesize an in‐silico quantitative marker (ISNLD) that enables personalized risk stratification for intrahepatic and extrahepatic outcomes of high‐risk individuals of NAFLD.
Lushan Xiao+14 more
wiley +1 more source
Background/Purpose: Effective antiviral-therapy can reduce the risk of liver cirrhosis related hepatocellular carcinoma in patients with chronic hepatitis B and hepatitis C. Yet, the difference of hepatocellular carcinoma development in chronic hepatitis
Ming-Tsung Lin+8 more
doaj
Hepatitis C infection is often found in asymptomatic patients accidentaly during general check up, where there is increment levels of transaminases. Symptoms of hepatitis C infection include weakness, sleep disorders, nausea and so on.
Jefri Pratama Susanto+2 more
doaj +1 more source
BACKGROUND Interferon alfa is the only effective treatment for patients with chronic hepatitis C. Forty percent of patients have an initial response to this therapy, but most subsequently relapse.
G. Davis+10 more
semanticscholar +1 more source
The Iowa Viral Hepatitis Strategic Plan 2012-2016, August 26, 2014 [PDF]
Since the creation of the first viral hepatitis plan in 2004 several documents and advancements have been released that help Iowa plan and prioritize this revision of our hepatitis plan.
core
Advances in Single‐Cell Sequencing for Infectious Diseases: Progress and Perspectives
Single‐cell sequencing technologies uncover novel, unknown, and emergent features of many diseases. This review describes recent progress of single‐cell sequencing technologies and their applications in infectious diseases, summarizes the underlying commonalities of different infections and discusses future research directions, facilitating the ...
Mengyuan Lyu+13 more
wiley +1 more source
Production of interleukin-2 in response to synthetic peptides from hepatitis C virus E1 protein in patients with chronic hepatitis C: relationship with the response to interferon treatment [PDF]
BACKGROUND/AIMS: The role of cellular immunity in the clearance of hepatitis C virus after interferon therapy has not yet been elucidated. Here, we analyzed the T cell response to peptides from hepatitis C virus E1 protein in untreated and interferon ...
Borras-Cuesta, F. (Francisco)+6 more
core +1 more source
This review focuses on the immunomodulatory mechanisms of molecular hydrogen, the recent detection methods, and the classification advanced molecular hydrogen delivery materials. It provides a detailed description of their applications in areas such as arthritis, chronic wounds, cardiovascular injury, tumors, and bacterial infections, aiming to enhance
Gangfeng Li+9 more
wiley +1 more source